Faruqi & Faruqi Investigates Potential Claims Against Inovio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy INO?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Inovio Pharmaceuticals, specifically targeting investors who purchased securities between October 10, 2023, and December 26, 2025, aiming to provide legal support for affected investors.
- Overview of Allegations: The complaint alleges that Inovio and its executives violated federal securities laws, particularly citing deficiencies in the manufacturing of the CELLECTRA device, which hindered the timely submission of the INO-3107 Biologics License Application (BLA) and negatively impacted the company's market outlook.
- FDA Response and Stock Price Impact: On December 29, 2025, the FDA accepted Inovio's BLA but noted that the company failed to provide adequate information for accelerated approval, resulting in a 24.45% drop in Inovio's stock price to $1.73 per share, reflecting market concerns about the company's future prospects.
- Investor Action Call: Faruq & Faruqi encourages anyone with information, including former employees and shareholders, to contact the firm, emphasizing investors' rights and potential recovery opportunities in the class action lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.650
Low
3.00
Averages
7.33
High
13.00
Current: 1.650
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Class Action Reminder for Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, indicating potential investor losses.
- Financial Impact: On August 8, 2024, Inovio's second quarter financial results revealed a delay in submitting the BLA to the FDA due to manufacturing issues, causing the stock price to drop 3.1% to $8.44 per share the following day, directly affecting investor confidence.
- Regulatory Review Change: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA on a standard review timeline instead of the accelerated review, leading to a 24.45% stock price plunge to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The class action lawsuit alleges that Inovio failed to disclose critical negative information throughout the class period, including manufacturing deficiencies and insufficient information for accelerated approval, indicating that the company's positive statements about regulatory and commercial prospects lacked a reasonable basis, harming investor interests.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and its implications for the INO-3107 Biologics License Application, resulting in investor losses when the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in the number of securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record in securities litigation to ensure optimal legal representation in the class action, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Reminder of Class Action for Inovio Pharmaceuticals Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, involving investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- False Statement Allegations: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby affecting the company's future regulatory and commercial prospects.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a 24.45% drop in Inovio's stock price, reflecting market concerns about its future prospects.
- Investor Rights Reminder: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply to become the lead plaintiff in the federal securities class action, emphasizing the importance of investors actively protecting their rights in light of potential financial losses.
See More
Faruqi & Faruqi Encourages Inovio Investors to Discuss Legal Options
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased securities between October 10, 2023, and December 26, 2025, urging them to seek lead plaintiff status by the April 7, 2026 deadline, which could significantly impact their legal rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to protecting investor interests.
- Class Action Context: The class action lawsuit is filed against Inovio in federal court, and investors must act before the deadline to secure their claims, highlighting the potential implications of legal proceedings on investor rights.
- Company Disclosure Issues: Faruq & Faruqi reminds investors to pay attention to Inovio's disclosure practices, which may affect stock prices and investor confidence, emphasizing the importance of legal compliance in corporate governance.
See More
Investors Alert: Class Action Lawsuits Against Inovio and Paysafe
- Inovio Lawsuit Overview: A class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) alleges that the company made materially false or misleading statements between October 10, 2023, and December 26, 2025, resulting in significant investor losses, with a deadline of April 7, 2026, to apply for lead plaintiff status.
- Paysafe Legal Issues: Paysafe Limited (NYSE: PSFE) is facing a class action lawsuit for failing to disclose important facts regarding its e-commerce business and significant exposure to a single high-risk client, with affected investors needing to apply for lead plaintiff status by April 7, 2026, if they purchased shares between March 4, 2025, and November 12, 2025.
- Law Firm Background: Holzer & Holzer, LLC is an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicated to vigorously representing shareholders and investors in litigation since its founding in 2000, recovering hundreds of millions of dollars for victims of fraud and corporate misconduct.
- Investor Rights Protection: The firm encourages affected investors to contact them via their website or phone to discuss their legal rights and participate in the lawsuits to protect their investment interests.
See More
Inovio Pharmaceuticals Class Action Reminder for Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, indicating potential investor losses.
- Financial Impact: On August 8, 2024, Inovio's second quarter financial results revealed a delay in submitting the BLA to the FDA due to manufacturing issues, causing the stock price to drop 3.1% to $8.44 per share the following day, directly affecting investor confidence.
- Regulatory Review Change: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA on a standard review timeline instead of the accelerated review, leading to a 24.45% stock price plunge to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The class action lawsuit alleges that Inovio failed to disclose critical negative information throughout the class period, including manufacturing deficiencies and insufficient information for accelerated approval, indicating that the company's positive statements about regulatory and commercial prospects lacked a reasonable basis, harming investor interests.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and its implications for the INO-3107 Biologics License Application, resulting in investor losses when the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in the number of securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record in securities litigation to ensure optimal legal representation in the class action, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Reminder of Class Action for Inovio Pharmaceuticals Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, involving investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- False Statement Allegations: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby affecting the company's future regulatory and commercial prospects.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a 24.45% drop in Inovio's stock price, reflecting market concerns about its future prospects.
- Investor Rights Reminder: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply to become the lead plaintiff in the federal securities class action, emphasizing the importance of investors actively protecting their rights in light of potential financial losses.
See More
Faruqi & Faruqi Encourages Inovio Investors to Discuss Legal Options
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased securities between October 10, 2023, and December 26, 2025, urging them to seek lead plaintiff status by the April 7, 2026 deadline, which could significantly impact their legal rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to protecting investor interests.
- Class Action Context: The class action lawsuit is filed against Inovio in federal court, and investors must act before the deadline to secure their claims, highlighting the potential implications of legal proceedings on investor rights.
- Company Disclosure Issues: Faruq & Faruqi reminds investors to pay attention to Inovio's disclosure practices, which may affect stock prices and investor confidence, emphasizing the importance of legal compliance in corporate governance.
See More
Investors Alert: Class Action Lawsuits Against Inovio and Paysafe
- Inovio Lawsuit Overview: A class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) alleges that the company made materially false or misleading statements between October 10, 2023, and December 26, 2025, resulting in significant investor losses, with a deadline of April 7, 2026, to apply for lead plaintiff status.
- Paysafe Legal Issues: Paysafe Limited (NYSE: PSFE) is facing a class action lawsuit for failing to disclose important facts regarding its e-commerce business and significant exposure to a single high-risk client, with affected investors needing to apply for lead plaintiff status by April 7, 2026, if they purchased shares between March 4, 2025, and November 12, 2025.
- Law Firm Background: Holzer & Holzer, LLC is an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicated to vigorously representing shareholders and investors in litigation since its founding in 2000, recovering hundreds of millions of dollars for victims of fraud and corporate misconduct.
- Investor Rights Protection: The firm encourages affected investors to contact them via their website or phone to discuss their legal rights and participate in the lawsuits to protect their investment interests.
See More
